DVd Weekly Daratumumab-Bortezomib-Dexamethasone weekly Cycles 9 onwards
Multiple Myeloma in: Journal of the National Comprehensive Cancer Network Volume 9 Issue 10 (2011)
Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials | Scientific Reports
BORTDEXADARA Regimen
CASTOR study design. RRMM = relapsed or refractory multiple myeloma;... | Download Scientific Diagram
Additional Trials | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Overall survival in a cohort of multiple myeloma patients treated with... | Download Scientific Diagram
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
3630-Multiple myeloma DVd (daratumumab bortezomib dexamethasone) overview | eviQ
DVd-T SC Bortezomib-Daratumumab-Dexamethasone-Thalidomide v1
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Multiple myeloma current treatment algorithms | Blood Cancer Journal
Multiple myeloma current treatment algorithms | Blood Cancer Journal
CASTOR study design. RRMM = relapsed or refractory multiple myeloma;... | Download Scientific Diagram
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study - The Lancet Oncology
DVd - Darzalex + Velcade + dex - Myeloma | ChemoExperts
Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma - eBioMedicine
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US | SpringerLink
SYNOPSIS
Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma | Future Oncology
